Premium
Prazosin reduces drinking in AUD patients experiencing high level of withdrawal
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30691
Subject(s) - prazosin , alcohol , alcohol use disorder , medicine , anxiety , randomized controlled trial , psychiatry , receptor , antagonist , biochemistry , chemistry
The alpha‐1 blocker prazosin reduced drinking and improved anxiety and depressive symptoms in patients with alcohol use disorder (AUD) who exhibited high baseline levels of alcohol withdrawal symptoms, a 12‐week randomized trial has found. Those who experienced little or no withdrawal did not benefit from prazosin, leading to the conclusion that alcohol withdrawal symptoms moderate prazosin treatment response.